Pan Y, Wu H, Li Y
Department of Otolaryngology, the First Affiliated Hospital of Hainan Medical College, Haikou, 570203, China.
Department of Stomatology, the First Affiliated Hospital of Hainan Medical College.
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Jun 20;31(12):945-948. doi: 10.13201/j.issn.1001-1781.2017.12.012.
To investigate the effects of recombinant human IL-11 treatment on prognosis of patients with radiochemoradiotherapy in the treatment of nasopharyngeal carcinoma. Seventy-eight cases of nasopharyngeal carcinoma patients were selected as the research object, all the patients were equally divided into observation group and control group with 39 cases in each group accorded to the random draw envelope principle. The control group received conventional chemoradiotherapy treatment, the observation group received the IL-11 treatment based on the treatment in control group, the treatment cycles in the two groups were 2 cycles. After treatment, the total effective rates of the observation group and the control group were 87.2% and 59.0%, respectively, the total effective rate of the observation group was significantly higher than that of the control group (<0.05). There were 14 cases of grade 0 radiation-induced oral mucositis, 6 cases of grade Ⅰ, 14 cases of grade Ⅱ, 5 cases of grade Ⅲ in the observation group during the treatment; There were 28 cases of grade 0 radiation-induced oral mucositis, 5 cases of grade Ⅰ, 4 cases of grade Ⅱ, 2 cases of grade Ⅲ in the control group during the treatment there was statistically significant difference between the two groups (<0.05). After treatment, the serum CRP of observation group and control group were (5.32±1.92)mg/L and (12.44±2.48)mg/L that were significantly lower than before treatment of the (24.59±3.14)mg/L and (24.12±2.87)mg/L (<0.05), serum levels of CRP after treatment in the observation group were significantly lower than the control group (<0.05). After treatment, the pain scores of the observation group and the control group were significantly lower than those before treatment (<0.05), and the pain scores of the observation group after treatment were significantly lower than the control group (<0.05). The application of recombinant human IL-11 in the treatment of nasopharyngeal carcinom patients with radiochemoradiotherapy can decrease the expression of CRP, reduce the pain, relieve the oral mucositis and improve the prognosis.
探讨重组人白细胞介素-11治疗对鼻咽癌放化疗患者预后的影响。选取78例鼻咽癌患者作为研究对象，按照随机抽签信封原则将所有患者平均分为观察组和对照组，每组39例。对照组接受常规放化疗治疗，观察组在对照组治疗基础上接受白细胞介素-11治疗，两组治疗周期均为2个周期。治疗后，观察组和对照组的总有效率分别为87.2%和59.0%，观察组总有效率显著高于对照组（P<0.05）。治疗期间，观察组放射性口腔黏膜炎0级14例、Ⅰ级6例、Ⅱ级14例、Ⅲ级5例；对照组放射性口腔黏膜炎0级28例、Ⅰ级5例、Ⅱ级4例、Ⅲ级2例，两组比较差异有统计学意义（P<0.05）。治疗后，观察组和对照组血清CRP分别为（5.32±1.92）mg/L和（12.44±2.48）mg/L，均显著低于治疗前的（24.59±3.14）mg/L和（24.12±2.87）mg/L（P<0.05），且观察组治疗后血清CRP水平显著低于对照组（P<0.05）。治疗后，观察组和对照组疼痛评分均显著低于治疗前（P<0.05），且观察组治疗后疼痛评分显著低于对照组（P<0.05）。重组人白细胞介素-11应用于鼻咽癌放化疗患者治疗中可降低CRP表达，减轻疼痛，缓解口腔黏膜炎，改善预后。
